CD274 and neoplasm: Furthermore, future studies should directly compare the predictive performance of SF3A2 against established and emerging immune biomarkers, such as PD-L1 expression, tumor mutational burden (TMB), and MSI status, to determine its independent and complementary value in clinical decision-making.